Key facts
- It has raised $1.0M; the latest was Seed Round ($1.0M) in Jan 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Imbiome
- ·The full record, as it builds
Funding rounds
No funding rounds for Imbiome are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Imbiome
Developer of microbiome therapeutic technologies designed to increase the targeting and efficacy of live biotherapeutic products. The company aims to improve microbiome health by leveraging its proprietary molecular culture technology, enabling nanopharmaceutical companies to develop therapies that replace antibiotics for the treatment of gastrointestinal infectious diseases.
- Sector
- Healthcare
- HQ
- Voorheesville, NY, United States
- Founded
- 2023
- Employees
- 2
- Website
- imbiome.com/
- Ownership
- Privately Held (backing)
Imbiome doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Imbiome shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Imbiome in its N-PORT filings yet. We sweep new filings monthly.